Tazobactam sodium is an antibiotic belonging to the beta-lactamase inhibitor class. It is combined with Ceftolozane to enhance the activity of ceftolozane against various ESBL-producing Enterobacteriaceae and some *Bacteroides spp.*. It is intended for research use only and not for sale to patients. In vitro studies show that Tazobactam sodium (0.045 mg/mL Piperacillin/Tazobactam, 3 days) can induce oxidative stress and mitochondrial damage, leading to apoptosis in HK-2 cells when used with Piperacillin. In vivo, Tazobactam sodium (300-500 mg/kg of Piperacillin/Tazobactam, iv, single dose) has been observed to cause direct nephrotoxicity, including tubular damage and mitochondrial structure alteration, in C57BL/6 mouse models.
- Beta-lactamase inhibitor
- Extends activity of ceftolozane against ESBL-producing Enterobacteriaceae and *Bacteroides spp*.